Yahoo Finance14d
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and ...
Daily Monitor3d
Ugandan-made herbal medicines pass clinical trials - govt scientists
According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew ...
Researchers create new compound to potentially treat negative and positive symptoms of schizophrenia
We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea, for example. These ...
Nasdaq14d
Y-mAbs Therapeutics Presents Preclinical Data on GD2-SADA at SNMMI/ACNM Annual Meeting
The preclinical and translational pharmacokinetics data of GD2-SADA was presented at the SNMMI and ACNM Annual Meeting in Anaheim, California. Trial 1001 aims to refine the human pharmacokinetics ...
manilatimes2d
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...
Business Insider14d
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
while also advancing similar work with other planned SADA PRIT trials.” The abstract details are below: Abstract Title: “Preclinical and translational pharmacokinetics of GD2-SADA, a self-assembling ...
Morningstar14d
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
GD2-SADA PRIT with 177Lutetium-DOTA has demonstrated robust anti-tumor efficacy in preclinical studies and is currently being investigated in adults and adolescents with GD2-expressing solid ...
Rallybio begins Phase 2 trial for FNAIT prevention therapy
NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...
Nasdaq14d
Y-mAbs Presents GD2-SADA Pharmacokinetics Data At SNMMI And ACNM Annual Meeting
The poster, titled "Preclinical and Translational Pharmacokinetics of GD2-SADA ... regimen for the ongoing first-in-human or FIH Phase 1 Trial or Trial 1001. Y-mAbs is focused on advancing GD2 ...
Mena FN14d
Y-Mabs Presents Translational Pharmacokinetics Of GD2-SADA From Pretargeted RIT Platform At The SNMMI Mid-Winter And ACNM Annual Meeting
The poster titled“Preclinical and Translational Pharmacokinetics of GD2-SADA ... regimen of our ongoing first-in-human (FIH) Phase 1 Trial (Trial 1001),” said Norman LaFrance, M.D., Chief ...